Oligodendrocyte-protection and remyelination post-spinal cord injuries: a review.
In the past four decades, the main focus of investigators in the field of spinal cord regeneration has been to devise therapeutic measures that enhance neural regeneration. More recently, emphasis has been placed on enhancing remyelination and providing oligodendrocyte-protection after a spinal cord injury (SCI). Demyelination post-SCI is part of the cascading secondary injury that takes place immediately after the primary insult; therefore, therapeutic measures are needed to reduce oligodendrocyte death and/or enhance remyelination during the acute stage, preserving neurological functions that would be lost otherwise. In this review a thorough investigation of the oligodendrocyte-protective and remyelinative molecular therapies available to date is provided. The advent of new biomaterials shown to promote remyelination post-SCI is discussed mainly in the context of a combinatorial approach where the biomaterial also provides drug delivery capabilities. The aim of these molecular and biomaterial-based therapies is twofold: (1) oligodendrocyte-protective therapy, which involves protecting already existing oligodendrocytes from undergoing apoptosis/necrosis; and (2) inductive remyelination, which involves harnessing the remyelinative capabilities of endogenous oligodendrocyte precursor cells (OPCs) at the lesion site by providing a suitable environment for their migration, survival, proliferation and differentiation. From the evidence reported in the literature, we conclude that the use of a combinatorial approach including biomaterials and molecular therapies would provide advantages such as: (1) sustained release of the therapeutic molecule, (2) local delivery at the lesion site, and (3) an environment at the site of injury that promotes OPC migration, differentiation and remyelination.
Department of Biomedical Engineering, McGill University, Montreal, Quebec, Canada. mina.mekhail@mail.mcgill.ca
Mina
M
Mekhail
Guillermina
G
Almazan
Maryam
M
Tabrizian
D000818:Animals; D003711:Demyelinating Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends; D006801:Humans; D009413:Nerve Fibers, Myelinated / Q000187:drug effects / Q000502:physiology*; D009414:Nerve Growth Factors / Q000008:administration & dosage; D009416:Nerve Regeneration / Q000187:drug effects / Q000502:physiology*; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D009836:Oligodendroglia / Q000187:drug effects / Q000502:physiology*; D013119:Spinal Cord Injuries / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D013234:Stem Cells / Q000187:drug effects / Q000502:physiology
D009414:Nerve Growth Factors; D018696:Neuroprotective Agents